Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: A large single-center cohort study

Yu Zhang,Xing Xiong,Zhengzheng Fu,Hui Dai,Feirong Yao,Dong Liu,Shengming Deng,Chunhong Hu
DOI: https://doi.org/10.1016/j.ejrad.2019.108695
IF: 4.531
2019-11-01
European Journal of Radiology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>To determine the feasibility of whole-body diffusion-weighted imaging (WB-DWI) MRI for evaluation of response in patients with multiple myeloma (MM) following bortezomib-based therapy and to explore the direction of apparent diffusion coefficient (ADC) changes upon treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>Seventy-two MM patients who underwent WB-DWI MRI before and after bortezomib-based chemotherapy (21 weeks) were evaluated retrospectively. The estimated tumor volume (eTV) and ADC<sub>mean</sub> values before and after chemotherapy were calculated and compared between deep and non-deep responders. Predictive value of baseline ADC<sub>mean</sub> was calculated to predict the trend of ADC<sub>mean</sub> change following treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Fifty-five patients were classified as deep responders, and 17 cases were assigned as non-deep responders. For 327 focal lesions (FLs), the ADC<sub>mean</sub> value was significantly increased from baseline to post-treatment. However, the ADC<sub>mean</sub> value was significantly decreased following treatment in 846 representative diffuse lesions. Diffuse lesions showed a significantly decreased ADC<sub>mean</sub> value in deep responders, whereas no significant variation in ADC<sub>mean</sub> value in FLs was found between deep and non-deep responders. Baseline ADC<sub>mean</sub> at a specific value (0.808 × 10<sup>-3</sup>  mm<sup>2</sup>/s) yielded a maximum specificity (68.05%) and sensitivity (54.09%) in predicting increase of post-treatment ADC<sub>mean</sub>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The ADC<sub>mean</sub> value was significantly decreased in MM patients with diffuse pattern, while it was significantly increased in those with focal pattern following bortezomib-based treatment. WB-DWI MRI could be used to discriminate deep response to induction treatment in MM patients with diffuse infiltration pattern. Baseline ADC<sub>mean</sub> value might have a potential to predict the trend of ADC<sub>mean</sub> change following treatment.</p>
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?